Mme Docteur DOMINIQUE FOUQUE

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CABINET DU DR DOMINIQUE FOUQUE

  21 RUE ANTOINE FONTAINE, 97430 Le Tampon

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  The relation between renal function and serum sclerostin in adult patients with CKD

  Clinical journal of the American Society of Nephrology : CJASN · 2013

  📚 162 citations🎯 RCR 6.12Top 6% NIH

  Lire l'abstract Crossref ↓

  Summary Background and objectives Sclerostin, a bone antianabolic peptide involved in osteoporosis, is elevated in patients undergoing maintenance dialysis. However, there are no data for patients with early CKD. Design, setting, participants, & measurements Between January and July 2010, serum sclerostin and GFR (calculated by inulin clearance) were measured in 90 patients with CKD. Fasting blood samples were also drawn for determination of calcium, phosphorus, parathyroid hormone, bone alkaline phosphatase, and 25-OH vitamin D. Results Median GFR was 66.5 (interquartile range, 40.0–88.3) ml/min per 1.73 m2. Median sclerostin level was 53.5 (interquartile range, 37.5–77.2) pmol/L, was higher in patients with a GFR <60 ml/min per 1.73 m2, and was highest in those with ESRD. Sclerostin levels were significantly more elevated in men than women (P<0.05). An inverse relationship was found between sclerostin and GFR (r=−0.58; P<0.001), and a positive correlation was seen with age (r=0.34; P<0.01) and serum phosphate (r=0.26; P=0.02). In multiple regression analyses, GFR, sex, and serum phosphate were the only variables associated with serum sclerostin (P<0.001). Age lost its relationship with sclerostin level. Conclusions This is the first study reporting higher serum sclerostin levels starting at CKD stage III. GFR, sex, and serum phosphate were the only measures associated with sclerostin level, suggesting that the effect of age reported in the literature might instead be attributable to the altered renal function in the elderly. Correcting the serum phosphorus level may be associated with lower sclerostin levels.

• 2

  Towards a multidisciplinary approach to understand and manage obesity and related diseases

  Clinical nutrition (Edinburgh, Scotland) · 2017

  📚 130 citations🎯 RCR 5.56Top 7% NIH🔓 Open Access📄 PDF gratuit ↗
• 3

  Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort

  British journal of clinical pharmacology · 2018

  📚 78 citations🎯 RCR 4.78Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  AbstractAimsDrug prescription is difficult to manage in patients with chronic kidney disease (CKD). We assessed the prevalence and determinants of inappropriate drug prescriptions (whether contraindications or inappropriately high doses) with regard to kidney function in patients with CKD under nephrology care. We also assessed the impact of the equation used to estimate GFR on the prevalence estimates.MethodsThe CKD‐REIN cohort includes 3033 outpatients with CKD (eGFR between 15 and 60 ml min−1 1.73 m−2). We examined the daily doses of pharmacological agents prescribed at study entry. Inappropriate prescription was defined as the reported prescription of either a contraindicated drug or an indicated drug at an inappropriately high dose level with regard to the patient's GFR, as estimated with the CKD‐EPI equation, the de‐indexed CKD‐EPI equation, or the Cockcroft–Gault (CG) equation. Multivariate logistic regression was used to assess the determinants of inappropriate prescription risk.ResultsAt baseline, patients' median [interquartile range] number of drugs prescribed per patient was 8 [5–10]. Half of the patients had been prescribed at least one inappropriate drug. Anti‐gout, cardiovascular agents and antidiabetic agents accounted for most of the inappropriate prescriptions. The percentage of inappropriate prescriptions varied from one GFR equation to another: 52% when using the CKD‐EPI equation, 47% when using the de‐indexed CKD‐EPI equation and 41% with the CG equation. A multiple logistic regression analysis showed significantly higher odds ratios [95% confidence interval] for inappropriate prescriptions in male patients (1.28 [1.07; 1.53]), patients with diabetes (1.34 [1.06; 1.70]), those with a high BMI (1.58 [1.25; 1.99]), and those with a low GFR (10.2 [6.02; 17.3]). The risk of having at least one inappropriate prescription increased with the number of drugs per patient (P for trend < 0.0001) and therefore the odds ratio was 5.88 [4.17; 8.28] for those who received at least 11 prescribed medications compared to those who received fewer than 5.ConclusionOur results emphasize the complexity of drug management for CKD patients, for whom inappropriate prescription appears to be common.

Publications scientifiques (14) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche